Although brain Aβ deposition, tau protein hyperphosphorylation, and neuroinflammation are still the most important targets for the treatment of AD, it is increasingly recognized that the systemic changes also contribute to the pathological progress of AD (Wang J et al., 2017). Here, MAPT is linked to Alzheimer disease.